{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03571568",
            "orgStudyIdInfo": {
                "id": "17-BI-1206-02"
            },
            "organization": {
                "fullName": "BioInvent International AB",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma",
            "officialTitle": "Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcYRIIB), in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-bi-in-combination-with-rituximab-in-subjects-with-indolent-b-cell-non-hodgkin-lymphoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2018-05-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-09-22",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-09-22",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-05-17",
            "studyFirstSubmitQcDate": "2018-06-18",
            "studyFirstPostDateStruct": {
                "date": "2018-06-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-30",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "BioInvent International AB",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab",
            "detailedDescription": "This is a Phase 1/2a, dose escalation, consecutive-cohort, open-label trial of BI-1206 in combination with rituximab in subjects with indolent relapsed or refractory B-cell NHL, subtypes FL (except FL grade 3B), MZL, and MCL.\n\nThe trial consists of 2 main parts:\n\n* Phase 1 with two different Arms assessing IV or SC dosing of BI-1206,with dose escalation cohorts and selection of the RP2D of IV dosing (ivRP2D)and the RP2D of SC dosing (scRP2D) of BI-1206 in combination with rituximab (administered IV).\n* Phase 2a with two expansion cohorts evaluating the ivRP2D and scRP2D of BI-1206 in combination with rituximab (administered IV).\n\nSubjects in each phase (Phase 1 and 2a) and dosing Arms will receive 1 cycle of induction therapy with BI-1206 in combination with rituximab.\n\nSubjects who show clinical benefit (complete response \\[CR\\], partial response \\[PR\\], or stable disease \\[SD\\]) at Week 6 will continue onto maintenance therapy and receive BI-1206 ( using the same dose and route of administration as induction therapy) and rituximab once every 8 weeks (relative to previous maintenance dose) for up to 6 maintenance cycles, or up to 1 year from first dose of BI-1206 (whichever occurs first)."
        },
        "conditionsModule": {
            "conditions": [
                "Indolent B-Cell Non-Hodgkin Lymphoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Phase 1/2a, dose escalation, consecutive-cohort, open-label study trial of BI-1206 in combination with rituximab",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 98,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "BI-1206 IV",
                    "type": "EXPERIMENTAL",
                    "description": "BI-1206 IV Standard 3+3 Dose-Escalation Design",
                    "interventionNames": [
                        "Biological: BI-1206"
                    ]
                },
                {
                    "label": "BI-1206 SC",
                    "type": "EXPERIMENTAL",
                    "description": "BI-1206 SC Adaptive Dose Escalation Design (Bayesian logistic regression model (BLRM)",
                    "interventionNames": [
                        "Biological: BI-1206"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "BI-1206",
                    "description": "375 mg/m2, as per SmPC",
                    "armGroupLabels": [
                        "BI-1206 IV",
                        "BI-1206 SC"
                    ],
                    "otherNames": [
                        "Rituximab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Documenting AEs and SAEs and determining causality in relation to BI-1206 and/or rituximab",
                    "description": "Assess the safety and tolerability profile of BI-1206 when administered intravenously (IV) or subcutaneously (SC) in combination with rituximab in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL),subtypes follicular lymphoma (FL)(except FLgrade 3B), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL).",
                    "timeFrame": "During the 28-day treatment period on induction therapy"
                },
                {
                    "measure": "Determining the MTD of BI-1206 at the same dose level experiencing a BI-1206 or Rituximab-related or possibly related dose-limiting toxicity (DLT)",
                    "description": "Select the recommended Phase 2 dose (RP2D) by establishing the maximum tolerated dose (MTD) of BI-1206 given once weekly for 4 weeks, via IV infusion or SC injection in combination with rituximab.",
                    "timeFrame": "During the 28-day treatment period on induction therapy"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Evaluation of PK parameters for BI-1206.",
                    "description": "Study the PK profile of BI-1206 when administered IV or SC in combination with rituximab in subjects with relapsed or refractory B-cell NHL, subtypes FL (except FL grade 3B), MZL and MCL.",
                    "timeFrame": "Up to 1 year"
                },
                {
                    "measure": "Evaluation of PK parameters for rituximab during the BI-1206 treatment period.",
                    "description": "Study the PK profile of rituximab when administered in combination with BI-1206 (IV or SC).",
                    "timeFrame": "Up to 1 year"
                },
                {
                    "measure": "Evaluation of ADA response to BI 1206.",
                    "description": "Assess the immunogenicity of BI-1206 when administered IV or SC in combination with rituximab.",
                    "timeFrame": "Up to 1 year"
                },
                {
                    "measure": "Measurement of B cell depletion.",
                    "description": "Evaluate the effect of BI-1206 administered IV or SC in combination with rituximab on the depletion of B-cells.",
                    "timeFrame": "Up to 1 year"
                },
                {
                    "measure": "Assessment of overall response rate (ORR) according to the response criteria for malignant lymphoma (Cheson, 2014).",
                    "description": "Assess possible anti-tumor activity of BI-1206 administered IV or SC in combination with rituximab at Week 6 after first dose of BI-1206 and for subjects who continue during maintenance therapy.",
                    "timeFrame": "Up to 1 year"
                },
                {
                    "measure": "CD32b protein expression levels",
                    "description": "Investigate CD32b protein expression levels; evaluate any potential correlation with clinical responses.",
                    "timeFrame": "Up to 1 year"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Measurement of PROs using the PRO-CTCAE questionnaire.",
                    "description": "Evaluate patient-reported outcomes (PROs)in subjects receiving BI-1206",
                    "timeFrame": "Up to 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Are \u2265 18 years of age by initiation of study treatment.\n* Have B-cell NHL proven by histology, with histological subtypes limited to follicular lymphoma (FL) (except FL grade 3B), MCL and marginal zone lymphoma (MZL).\n* Have measurable nodal disease\n* Are willing to undergo lymph node biopsies or biopsies of other involved tissue\n* Have relapsed disease or disease refractory to conventional treatment or for which no standard therapy exists.\n* Have received at least one line of conventional previous therapy which must include at least one rituximab-based regimen.\n* Have a life expectancy of at least 12 weeks\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Have CD20+ malignancy\n* Have hematological and biochemical indices within prespecified ranges\n\nExclusion Criteria:\n\n* Have had an allogenic bone marrow or stem cell transplant within 12 months\n* Have presence of active chronic graft versus host disease\n* Have current leptomeningeal lymphoma or compromise of the central nervous system.\n* Have transformed lymphoma from a pre-existing indolent lymphoma.\n* Have Waldenstrom's Macroglobulinemia or FL3B,\n* Need systemic doses of prednisolone \\>10 mg daily (or equipotent doses of other corticosteroids) while on the study trial other than as pre-medication.\n* Have known or suspected hypersensitivity to rituximab or BI-1206.\n* Have cardiac or renal amyloid light-chain amyloidosis.\n* Have received any of the following:\n* Chemotherapy or small molecule products with 2 weeks of first dose of BI-1206\n* Radiotherapy (except for focal symptomatic control of lymphadenopathy) within 4 weeks\n* Immunotherapy within 8 weeks\n* Have ongoing toxic manifestations of previous treatments.\n* Have the ability to become pregnant (or already pregnant or lactating/breastfeeding).\n* Have had major surgery from which the subject has not yet recovered.\n* Are at high medical risk because of non-malignant systemic disease including active infection on treatment with antibiotics, antifungals or antivirals.\n* Are serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).\n* Have an active, known or suspected autoimmune disease.\n* Have concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association \\[NYHA\\]),\n* Have current malignancies of other types",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Erika B\u00e5geman",
                    "role": "CONTACT",
                    "phone": "+46706126618",
                    "email": "erika.bageman@bioinvent.com"
                },
                {
                    "name": "Andres McAllister, MD, PhD",
                    "role": "CONTACT",
                    "email": "andres.mcallister@bioinvent.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Mats Jerkeman, MD PhD",
                    "affiliation": "Senior Consultant and Adjunct Professor, Skane Univ Hospital, Lund, Sweden",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Emory University Hospital",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jonathon Cohen, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40207",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Don Stevens, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "Hospital S\u00e3o Rafael",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Salvador",
                    "state": "Bahia",
                    "country": "Brazil",
                    "contacts": [
                        {
                            "name": "Cacilda",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Marco Aurelio Salvino De Araujo, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -12.97111,
                        "lon": -38.51083
                    }
                },
                {
                    "facility": "Hospital de Cl\u00ednicas de Porto Alegre",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Porto Alegre",
                    "state": "Rio Grande Do Sul",
                    "country": "Brazil",
                    "contacts": [
                        {
                            "name": "Suellen",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Laura Maria Fogliatto, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -30.03306,
                        "lon": -51.23
                    }
                },
                {
                    "facility": "A.C. Camargo Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "S\u00e3o Paulo",
                    "country": "Brazil",
                    "contacts": [
                        {
                            "name": "RN",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Ana Costa Cordeiro, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -23.5475,
                        "lon": -46.63611
                    }
                },
                {
                    "facility": "Hospital Israelita Albert Einstein",
                    "status": "NOT_YET_RECRUITING",
                    "city": "S\u00e3o Paulo",
                    "country": "Brazil",
                    "contacts": [
                        {
                            "name": "RN",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Guilherme Perini, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -23.5475,
                        "lon": -46.63611
                    }
                },
                {
                    "facility": "Hospital S\u00edrio-Liban\u00eas",
                    "status": "NOT_YET_RECRUITING",
                    "city": "S\u00e3o Paulo",
                    "country": "Brazil",
                    "contacts": [
                        {
                            "name": "Ana Rita Da Fonseca, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -23.5475,
                        "lon": -46.63611
                    }
                },
                {
                    "facility": "Krankenhaus Nordwest Klinik f\u00fcr Onkologie und H\u00e4matologie",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Frankfurt",
                    "state": "Hessen",
                    "country": "Germany",
                    "contacts": [
                        {
                            "name": "Eckhart Weidmann, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.11552,
                        "lon": 8.68417
                    }
                },
                {
                    "facility": "Robert Bosch Hospital, Dep of Hematology, Oncology and Palliative care",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Stuttgart",
                    "country": "Germany",
                    "contacts": [
                        {
                            "name": "RN",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Nicola Giesen, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.78232,
                        "lon": 9.17702
                    }
                },
                {
                    "facility": "Szpital Specjlistyczny",
                    "status": "TERMINATED",
                    "city": "Grudziadz",
                    "zip": "86-300",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 53.48411,
                        "lon": 18.75366
                    }
                },
                {
                    "facility": "Ma\u0142opolskie Centrum Medyczne",
                    "status": "TERMINATED",
                    "city": "Krakow",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 50.06143,
                        "lon": 19.93658
                    }
                },
                {
                    "facility": "Hospital ICO, Trias i Pujol",
                    "status": "RECRUITING",
                    "city": "Badalona",
                    "state": "Barcelona",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Juan Manuel Sancho Cia, MA",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.45004,
                        "lon": 2.24741
                    }
                },
                {
                    "facility": "Hospital de la Santa Creu i Sant Pau, Dep Hematologia",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Silvana Novelli, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitari Vall d'Hebron",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Pablo Abrisqueta Costa, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Institut Catal\u00e0 d'Oncologia, L'Hospitalet de Llobregat",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Eva Domingo Domenech, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital General Universitario Gregorio Mara\u00f1on-Oncolog\u00eda M\u00e9dica",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Mariana Bastos Oreiro, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario HM San Chinarro",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Madrid",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Jaime Perez de Oteyza, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "University Hospital Fundacion Jimenez Diaz",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Raul Cordoba Mascunano, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario Virgen de la Arrixaca",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Murcia",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Joaquin Gomez Espuch, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.98704,
                        "lon": -1.13004
                    }
                },
                {
                    "facility": "Hospital Virgen Macarene",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Seville",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Sergio Orteg\u00f3n Alcaide, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.38283,
                        "lon": -5.97317
                    }
                },
                {
                    "facility": "Department of Oncology, Sk\u00e5ne University Hospital",
                    "status": "RECRUITING",
                    "city": "Lund",
                    "zip": "SE-22185",
                    "country": "Sweden",
                    "contacts": [
                        {
                            "name": "Mats Jerkeman, PI",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Mats Jerkeman, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 55.70584,
                        "lon": 13.19321
                    }
                },
                {
                    "facility": "Department of Oncology, Academical Hospital",
                    "status": "TERMINATED",
                    "city": "Uppsala",
                    "zip": "751 85",
                    "country": "Sweden",
                    "geoPoint": {
                        "lat": 59.85882,
                        "lon": 17.63889
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "All information concerning the product as well as any matter concerning the operation of the Sponsor, such as clinical indications for the drug, its formula, methods of manufacture and other scientific data relating to it, that have been provided by the Sponsor and are unpublished, are confidential and must remain the sole property of the Sponsor. The Investigator will agree to use the information only for the purposes of carrying out this study and for no other purpose unless prior written permission from the Sponsor is obtained.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "CSR"
            ],
            "timeFrame": "Within one year from end of study",
            "accessCriteria": "Paper copy of CSR"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                },
                {
                    "id": "D000016393",
                    "term": "Lymphoma, B-Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "asFound": "B-Cell Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "asFound": "Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "asFound": "B-Cell Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000069283",
                    "term": "Rituximab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M373",
                    "name": "Rituximab",
                    "asFound": "Infusion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                }
            ]
        }
    },
    "hasResults": false
}